Salute e Benessere
Navamedic ASA: Imdur® distribution agreement extended to 2032
Imdur® (isosorbide mononitrate), is a prescription medication used to prevent angina pectoris due to heart disease. It was first launched in Europe in 1985. Navamedic commenced distribution of the product as part of a strategic partnership and long-term distribution agreement with TopRidge Pharma Limited in 2016.
"Imdur® remains an important product to Navamedic, and we appreciate the efforts made by TopRidge to update the Marketing Authorisations and to secure steady supplies to our markets. With the renewal of this agreement, we look forward to exploring further collaboration opportunities for additional products in the future," Gamborg Andreassen concludes.
The effective date of the agreement is 1 January 2025 , and the revised terms of the agreement are implemented from this date even though the signature date is 29 April 2025 .
Kathrine Gamborg Andreassen , CEO, Navamedic
Mobile: +47 951 78 680
E-mail: kathrine@navamedic.com
Lars Hjarrand, CFO, Navamedic
Mobile: +47 917 62 842
E-mail: lars.hjarrand@navamedic.com
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/navamedic-asa/r/navamedic-asa--imdur--distribution-agreement-extended-to-2032,c4143035
View original content:https://www.prnewswire.co.uk/news-releases/navamedic-asa-imdur-distribution-agreement-extended-to-2032-302441524.html